Patients with primary central nervous system lymphoma (PCNSL) treated in the 'real-world' setting do not represent those treated on clinical trials and might not be treated similarly. We studied characteristics and variability in care for 113 newly diagnosed PCNSL patients treated at 5 institutions in the Chicago area between 2000 and 2012. In 111 patients, single modality therapy with a high dose methotrexate (HD-MTX) regimen +/À rituximab, was most commonly employed (n = 65), and 34 underwent radiotherapy (+/À systemic therapy). Fifty-eight of 108 patients received rituximab. Twenty-nine of 110 patients (26%) received intrathecal chemotherapy (ITC). Overall response rate was 80% (47% complete responses). With a median follow-up of 18Á7 months, median overall survival (OS) was 65Á2 months. In univariate analysis, HD-MTX (median OS 72Á7 vs. 2Á7 months, P < 0Á001) and rituximab (median not reached versus 28Á4 months, P = 0Á005) impacted OS favourably. This significance was sustained regardless of immune status and in multivariate analysis. Whole brain radiotherapy (WBRT) resulted in a trend for improved OS as compared with systemic therapy alone (P = 0Á09), while ITC did not impact survival. Clinical practice has evolved to exclude WBRT and ITC while incorporating rituximab with clinical outcomes comparable in immunocompetent/compromised patients and similar to those achieved in recent clinical trials.
Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) that arises from the brain parenchyma, eyes, meninges or spinal cord in the absence of systemic disease (Batchelor & Loeffler, 2006) . Although its incidence has markedly increased in the last three decades (Rubenstein et al, 2008; Villano et al, 2011; Ostrom et al, 2015) , it remains a rare entity comprising less than 3% of all cases of NHL (Dolecek et al, 2012) .
Due to its rarity, treatment recommendations for PCNSL have been more consensus-based as opposed to validated by randomized clinical trials. PCNSL treated with whole brain radiotherapy (WBRT) alone produced short-lived responses with dismal long-term survival ranging from 10-18 months (Nelson et al, 1992) . The addition of high-dose methotrexate (HD-MTX) to radiation improved survival compared with historical controls treated with radiation alone (DeAngelis & Iwamoto, 2006; Morris et al, 2013; Thiel et al, 2010) . However, a significant number of patients were not cured, with combined modality therapy increasing the risk of neurotoxicity, particularly in the elderly (Abrey et al, 1998 (Abrey et al, , 2000 Correa et al, 2009; Gavrilovic et al, 2006) .
More recently, clinical practice has shifted to an approach that includes poly-chemotherapeutic regimens with immunotherapy, often with the intent of reducing the radiation dose of WBRT or omitting it altogether (Rubenstein et al, 2013; Batchelor et al, 2003; Ferreri et al, 2009; Omuro et al, 2015; Ferreri et al, 2016) . However, to date, these efforts have not been validated prospectively and it remains unclear whether withholding WBRT compromises survival (Thiel et al, 2010; Korfel et al, 2015) . This needs to be research paper carefully considered in the context of the favourable outcomes recently reported in the phase I/II Radiation Therapy Oncology Group (RTOG) 0227 trial which employed WBRT (36 Gy) consolidation after MTR [methotrexate, temozolomide (TMZ) , rituximab] induction (Glass et al, 2016) . Similarly, it is not yet known whether rituximab and combination chemotherapy are more effective when given with or without radiation therapy (Kansara et al, 2015; Holdhoff et al, 2014) . There are even less data pertaining to the benefit of rituximab in the immuno-compromised population with PCNSL (Newell et al, 2004) . As such, we sought to: (i) identify whether evolving patterns of care in a 'realworld' setting have impacted outcomes in newly diagnosed PCNSL; (ii) consider if such practice patterns offer reasonable outcomes in the immuno-compromised subset; and (iii) determine whether 'real-world' practice patterns and clinical outcomes are comparable to those reported in recent clinical trials.
Methods
We created a multicentre retrospective registry at 5 academic centres in the Chicago area that included patients aged ≥18 years diagnosed with PCNSL between 2000 and 2012. The study protocol was approved by the institutional review board of each institution. Pathology was reviewed by haemato-pathologists at participating institutions, not centrally. Those with primary ocular lymphoma or a histology other than diffuse large B-cell lymphoma (DLBCL) were excluded. When available, human immunodeficiency virus (HIV) status was documented. Those with HIV, known prior exposure to immuno-suppressive therapy for co-morbid conditions and/ or a diagnosis of post-transplant lympho-proliferative disorder (PTLD), were classified as 'immuno-compromised'. Baseline disease and patient characteristics, administered treatments (including observation) and clinical outcomes were assessed in 113 patients and entered into a centralized database. All decisions on clinical management and response evaluations to initial treatment were obtained through the review of individual medical records.
Statistical analysis
Patient baseline characteristics were summarized using descriptive statistics. Clinical outcomes of interest were response rates to first-line therapy and overall survival (OS). Reponses were determined independently by each patient's treating physician and categorized as either complete response (CR), partial response (PR), stable disease (SD) or progressive disease. Data on relapses were not recorded. Overall survival was defined as time from date of PCNSL diagnosis to death or last follow-up. Univariate analyses (UVA) for response rates and OS were performed using each of the pre-treatment variables collected. Differences in categorical data with respect to clinical outcomes were calculated using the Fisher exact test with significance defined as P ≤ 0Á05. For the entire cohort, OS was analysed using the Kaplan Meier method with differences assessed by Log-Rank. These analyses were then repeated for the HIV positive and immuno-compromised subsets of patients. Data were analysed using the Statistical Package for the Social Sciences (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA: IBM Corp.).
Results

Baseline patient characteristics
We identified 113 patients with DLBCL-subtype PCNSL; baseline demographic and clinical characteristics are summarized in Table I . The median age of patients was 61 (range 24-88) years, 60 were males (53%), 46 had an elevated lactate dehydrogenase (LDH; 41%), 73 had deep structure involvement (66%), and 37 had cerebrospinal fluid (CSF) involvement (34%). HIV status was obtained in 92 patients with 15 patients having the infection. However, 26 patients were deemed to have a state of immuno-compromise, including those patients with HIV/acquired immunodeficiency syndrome (AIDS) and/or co-morbid conditions requiring use of immuno-suppressive agents/PTLD.
Variability in treatment strategies
Treatment data were acquired in 111 patients, including the choice to defer therapy (n = 6) as noted in Table I . Ninetyseven of 111 patients (87%) received a HD-MTX containing regimen and 58 of 108 patients (54%) were exposed to rituximab. Information on doses and number of cycles of HD-MTX used across the participating institutions could not be reliably obtained. Poly-chemotherapy regimens were used in the majority of patients -77 patients (70%) received a multi-drug regimen +/À rituximab, all containing HD-MTX; the most common agents used in combination with HD-MTX included vincristine, procarbazine and cytarabine. Six patients were not treated; the reasons for this were unclear given the retrospective nature of this study, but review of clinical features for these patients was suggestive of a selection bias with poor performance status and/or older age noted in this group. Whole brain radiation therapy was omitted in the majority of patients -34 patients of 111 (31%) received WBRT, either in combination with systemic therapy (n = 29, 26%), including one patient who underwent autologous transplantation, or alone (n = 5, 5%); WBRT was entirely omitted in 77 patients (69%). Of these 77 patients, 65 patients received a HD-MTX containing regimen +/À rituximab, 3 received a HD-MTX containing induction +/À rituximab followed by consolidation with autologous transplantation, 2 were treated with rituximab monotherapy, 1 was treated with TMZ + rituximab, and 6 were left untreated. Data on the 
Clinical outcomes
The median follow-up in surviving patients was 18Á7 months (0Á1-106Á4). Response data were obtained in 85 treated patients. Overall response rates (CR + PR) were 80%, with 47% CR and 33% PR. In univariate analysis, the use of HD-MTX and rituximab were both associated with achievement of CR (P = 0Á004 and P = 0Á02) whereas WBRT and/or the use of ITC did not appear to improve response rates. Response rates were also unaffected by age, gender, cell of origin, deep structure involvement, LDH and HIV status. Data on retreatment following relapse or progression was not collected.
Median OS for the whole cohort was 65Á2 months [95% confidence interval (CI) 28Á4-not reached (NR)]. We could not calculate the International Extranodal Lymphoma Study Group (IELSG) risk score (Ferreri et al, 2003) nor utilize the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model , given large amounts of missing data collectively for some parameters, such as Eastern Cooperative Oncology Group performance status (ECOG PS), CSF protein and LDH. Of note, for those patients in whom information on IELSG risk score factors were available, age, LDH and deep structure involvement were not prognostic of OS but there was a trend for significant impact of protein levels in CSF; the impact of ECOG PS was not analysed. In univariate analysis, HD-MTX, rituximab and depth of response were the only variables that clearly impacted survival. The median OS for patients exposed to HD-MTX (n = 97) was 72Á6 vs. 2Á7 months for those not treated with a HD-MTX containing regimen (n = 14, Fig 1A, P < 0Á0001 ). The median OS for patients receiving rituximab (n = 58) was NR versus 28 months in those unexposed to rituximab (n = 50, Fig 1B,  P = 0Á005) . The rituximab-exposed cohort had a higher likelihood of being treated with HD-MTX as compared to the rituximab-unexposed group (95% vs. 81%, P = 0Á036). There was a trend for improved OS with WBRT ( Fig 1C, P = 0Á087) . Although patients receiving WBRT had similar clinical characteristics to those who did not receive WBRT, the radiation cohort was more likely to be treated with ITC (44% vs. 18%, P = 0Á005). Similarly, the presence of elevated CSF protein levels also showed signals of negative impact on OS. Use of ITC did not correlate with survival (Fig 1D) . In the HIV/immuno-compromised subsets (n = 26), exposure to HD-MTX and/or rituximab was associated with improved OS whereas WBRT and CSF protein levels did not correlate with survival (Table II) . It is uncertain whether these patients were managed concurrently by initiating HIV-directed therapy and/or stopping immunosuppressive agents. The immuno-compromised group had comparable clinical characteristics to the immunocompetent cohort and was treated similarly with respect to use of WBRT, rituximab and ITC. The exception to this was that a greater proportion with immuno-compromise had a higher LDH (50% vs. 32%, P = 0Á045) and a smaller proportion received HD-MTX (65% vs. 90%, P = 0Á009). Despite this, OS in this subset was not compromised.
For multivariate analyses, to optimize sample size and focus on impact of various treatment strategies on PCNSL, we included only the following: age, sex, deep structure involvement, LDH, use of HD-MTX, rituximab, WBRT and ITC (Table III) . With this analysis, high dose-MTX had a strongly significant impact on OS (Hazard ratio [HR] 0Á08, P < 0Á0001). Rituximab exposure was independently associated with an improvement in survival (HR 0Á44, P = 0Á017), as was WBRT (HR 0Á44, P = 0Á049). The other variables did not appear to affect survival. In multivariate analysis for the immuno-compromised population, we looked at exposure to HD MTX, WBRT, ITC and rituximab. LDH and clinical response were also included as they were significant in univariate analysis. Exposure to rituximab (HR 0Á055, P = 0Á006) and achievement of response (either CR or PR; HR = 0Á05, P = 0Á009) maintained significant impact on survival. 
Discussion
To date, the literature on PCNSL has lacked data on 'real world' patterns of care and our report examines such data. Our study confirms the lack of a clear standard in treating PCNSL for those treated outside of a clinical trial setting.
Our findings however are in line with general universal practice trends of relying on systemic therapeutic agents that cross the blood brain barrier, with HD-MTX being the preferred agent, and the omission of WBRT. Less than half of our patients were treated with WBRT across the 5 institutions participating in this study. This apparent movement away from WBRT mirrors the design of a number of recent clinical trials, including the German prospective phase III study designed to address the question of whether a regimen of HD-MTX alone was non-inferior to combined modality treatment with chemotherapy and WBRT (Thiel et al,2010; Korfel et al, 2015) . Similarly, the RTOG completed accrual with data maturing for a randomized phase II trial addressing the utility of adjunctive low dose (32Á5 Gy) WBRT versus no WBRT after induction with HD-MTX, vincrisitine, procarbazine and rituximab (NCT01399372). Our data suggest similar outcomes in patients irrespective of exposure to WBRT (median OS of NR (WBRT employed) versus 31Á4 months (no WBRT), P = 0Á09). These results are comparable to those of the aforementioned German trial -median survival in an intent-to-treat analysis of the trial showed no difference in OS (32Á4 vs. 36Á1 months, HR 0Á98, 95% CI 0Á79-1Á26) (Thiel et al, 2010; Korfel et al, 2015) . Of note, the failure of the trial to meet its primary endpoint of non-inferiority for a 'no radiation' approach is owing to the several complexities in its design and execution -although OS was similar in per-protocol and intent-to-treat analyses in patients receiving WBRT versus not, the non-inferiority margin was very small. Moreover, the substantial amount of crossover made a reliable comparison of study arms challenging.
Recently, the RTOG 0227, a phase I/II trial reported results of HD-MTX, TMZ and rituximab, followed by hyperfractionated WBRT and subsequent TMZ (Glass et al, 2016) . The estimated median OS was 7Á5 years with a lower limit on the 95% CI of 4Á3 years. Although a direct comparison cannot reliably be made, median OS in our patients was seemingly lower with a median OS of 65Á2 months. We believe that this discrepancy however, is best attributed to the use of maintenance rather than the incorporation of WBRT in the RTOG study. Taken collectively with the known neuro-cognitive toxicity of WBRT, particularly in the elderly (Abrey et al, 1998 (Abrey et al, , 2000 Correa et al, 2009; Gavrilovic et al, 2006) , the need for WBRT remains a valid question. The RTOG 1116 trial will probably provide additional insight in this matter (NCT01399372). Until then, our data demonstrates that the migration away from WBRT in 'real-world' practice may not compromise outcomes and provides some direction for clinical practice.
There is a dearth of prospective evidence specifically investigating whether omitting ITC impacts survival (Pels et al, 2009 ). In our study, ITC was administered in less than onethird of patients and did not correlate with improvement in OS, consistent with the findings of several other retrospective studies (Ferreri et al, 2002; Khan et al, 2002) . The practice of omitting ITC in our population parallels the platform used by co-operative groups for recent and ongoing clinical trials (Rubenstein et al, 2013, NCT01399372) . Of note, patients in our cohort with CSF involvement (n = 37) did not appear to have shortened survival either (P = 0Á92). Nine patients with CSF involvement received ITC; the therapeutic benefit of ITC to this subset could not be deciphered in our analysis given the small sample size.
Our study represents the largest retrospective series, outside of clinical trials, that evaluates the utility of rituximab as an adjunct to cytotoxic therapy in PCNSL, showing similar results to most retrospective series of improved outcomes in PCNSL (Holdhoff et al, 2014; Birnbaum et al, 2012; Gregory et al, 2013) . Doses of MTX and/or rituximab, use of additional cytotoxics and number of cycles were variable across these studies. Higher and/or more frequent doses of rituximab have been cited as a potential explanation for the benefits seen with adjunctive immunotherapy in these studies as compared to the lack of benefit reported by the British Columbia Cancer Agency (BCCA) with HD-MTX + rituximab (Kansara et al, 2015) . Our results are also consistent with those of the IELSG-32 study, a multi-centre prospective randomized trial (Ferreri et al, 2016) . Results of the first randomization of this study were recently reported: 219 assessable patients under the age of 70 years were randomized in a 1:1:1 fashion to either a combination of HD-MTX 3Á5 g/m 2 and cytarabine (Arm A) versus the same regimen plus rituximab (Arm B) versus all three drugs plus thiotepa (the MATRix regimen, Arm C) with a primary endpoint of complete remission rate, analysed by modified intention-to-treat. Complete response rates were 23% (HR 0Á46, 95% CI 0Á28-0Á74) versus 30% (HR 0Á61, 0Á40-0Á94) versus 49% (95% CI 38-60) in Arms A, B and C respectively, suggesting a benefit to the addition of rituximab. The results of the second randomization of this study, (patients who attain CR/ PR or SD after four cycles of chemotherapy have undergone a second randomization to WBRT or autologous stem cell transplantation), will shed some light on the utility of radiation as compared to a dose-intensive chemotherapy approach. Our data also informs, for the first time, on clinical practice for PCNSL in the immuno-compromised population, a group that has historically been challenging to assess prospectively as it is typically excluded from clinical trials. To our knowledge, our study is singular in evaluating the role of rituximab in the treatment of PCNSL in the immuno-compromised host. Although most would agree that rituximab is safe and improves survival in the HIV population treated for systemic B-cell NHLs (Alwan et al, 2015; Barta et al, 2013) , experience with rituximab for PCNSL in the immuno-compromised host is limited to case studies (Wolf et al, 2014) . We show that a There are inherent limitations to our retrospective study including our small sample size, lack of information on performance status, lack of data at relapse and short follow-up. These limitations may also explain the comparably modest contributions of HD-MTX to survival in immuno-compromised subset as compared to our cohort as a whole. Possibly more importantly, as with all retrospective studies of therapeutic interventions, an inherent selection bias is present, as reflected by the tendency to de-escalate care in older patients with poorer performance status and the minimal use of consolidation with high-dose chemotherapy with stem cell rescue in our cohort.
The median OS in our population was 65Á2 months. This compares favourably to historical data and is similar to the results of recent clinical trials evaluating the utility of WBRT and/or rituximab. This lends support to our cohort being broadly representative of the overall PCNSL population both on and off clinical trial. However, PCNSL remains an aggressive disease with poor outcomes for which few advancements have been made -for over a decade now, clinical practice and clinical trials have played on variations of dose intensification either with poly-chemotherapeutic strategies with or without autologous transplant and/or WBRT without much progress in establishing a clear standard. In the 'real-world' setting, treatment strategies have evolved in parallel with contemporary prospective trial design, both in Europe and North America (Ferreri et al, 2016; Thiel et al, 2010; Korfel et al, 2015; Birnbaum et al, 2012; NCT01399372) , for frontline PCNSL treatment, moving away from WBRT and ITC while incorporating rituximab. With such changes, outcomes have remained similar, if not improved, as compared to historical trials utilizing HD-MTX, ITC and WBRT without immunotherapy (Fisher et al, 2005; Abrey et al, 2000) . Furthermore, the efficacy of these practices have been maintained in the immuno-compromised host. Though our study demonstrates some variability and evolution in practice, it is ultimately representative of a limited repertoire of available treatments. Fortunately, we are now starting to see the incorporation of novel agents including bruton tyrosine kinase inhibitors (NCT02315326) and PD-1 (also termed PDCD1) inhibitors, which may change the therapeutic landscape of PCNSL (NCT02779101).
